| Proportion with APRI >1.5 (significant fibrosis) | Odds ratio (n = 726) | p value | Adjusted odds ratio (n = 726) | p value |
---|---|---|---|---|---|
Hepatitis C antibody status | |||||
 Negative | 2.1% (11/531) | 1.00 |  | 1.00 |  |
 Positive | 10.0% (23/231) | 5.16 (2.50-10.65) | <0.001 | 2.53 (1.03-6.23) | 0.044 |
Hepatitis B surface antigen | |||||
 Positive | 1.4% (2/146) | 1.00 |  | 1.00 |  |
 Negative | 5.2% (32/616) | 3.28 (0.89-12.02) | 0.074 | 3.28 (0.85-12.71) | 0.085 |
History of injecting drug use | |||||
 No | 1.8% (11/603) | 1.00 |  | 1.00 |  |
 Yes | 15.3% (23/150) | 9.15 (4.40-19.01) | <0.001 | 3.51 (1.39-8.89) | 0.008 |
WHO stagea | |||||
 1–2 | 2.6% (16/605) | 1.00 |  | 1.00 |  |
 3–4 | 12.4% (18/145) | 5.02 (2.52-10.02) | <0.001 | 3.47 (1.51-7.99) | 0.003 |
CD4 counta | |||||
  > 350 cells/mm3 | 3.9% (22/563) | 1.00 |  |  |  |
 201-350 cells/mm3 | 5.3% (7/132) | 1.46 (0.62-3.42) | 0.381 |  |  |
  ≤ 200 cells/mm3 | 8.2% (4/49) | 2.32 (0.80-6.67) | 0.119 |  |  |
Smoker at postnatal cohort enrolment | |||||
 No | 2.7% (11/409) | 1.00 |  | 1.00 |  |
 Yes, current smoker | 6.8% (23/340) | 2.59 (1.26-5.33) | 0.010 | 1.06 (0.46-2.42) | 0.896 |
Age | |||||
 Per increasing year |  | 1.10 (1.03-1.18) | 0.007 | 1.08 (0.99-1.18) | 0.070 |
Postnatal ARTb | |||||
 Yes | 4.0% (10/253) | 1.00 |  | 1.00 |  |
 No | 4.8% (24/500) | 1.15 (0.55-2.41) | 0.715 | 3.08 (1.23-7.74) | 0.017 |